Assessment of Eloquent Function in Brain Tumor Patients

Sponsor
University of Nebraska (Other)
Overall Status
Recruiting
CT.gov ID
NCT01535430
Collaborator
(none)
75
1
161
0.5

Study Details

Study Description

Brief Summary

Purpose of the study:

AIM 1 Prospectively collect pre-operative (fMRI, DTI, MEG) and intra-operative mapping data in patients with intra-axial brain tumors to assess how well each modality predicts the location of eloquent brain function. In addition, each modality will be compared with the other.

AIM 2 Assess reorganization of eloquent brain function and plasticity in patients with intra-axial brain tumors. This will be accomplished by prospectively collecting post-operative mapping studies and neuropsychological tests to compare them to prior mapping studies as stated above.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Any patient with a primary or metastatic brain tumor in or near an eloquent area would be eligible for participation in the study assuming no contraindications to any of the studies or operative procedure.

    Pre-operative:

    Evaluation will include clinical evaluation, neuropsychological testing, MRI brain with and without contrast, fMRI, DTI tractograms, and MEG studies as well as standard pre-operative work-up.

    Intra-operative:

    All non-invasive pre-operative mapping data will be incorporated into the operative procedure with the imaging tools that we routinely use during neurosurgical procedures. Patients will have awake mapping performed. Our usual standards of care will be followed during craniotomy, mapping, and tumor resection or biopsy.

    Post-operative:

    Patients will have routine post-operative care and assessment consisting of clinical examinations and imaging obtained within 24 hours post resection. They will have routine follow-up outpatient appointments after surgery which will include neurologic assessment and follow-up imaging (MRI with and without contrast) for their tumors as appropriate. The experimental portion of the protocol is incorporating repeat neuropsychological testing and mapping studies (fMRI, DTI, MEG) studies at 2 and 6 months post-surgery into their routine follow-up.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    75 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors
    Study Start Date :
    Jan 1, 2012
    Anticipated Primary Completion Date :
    Dec 1, 2024
    Anticipated Study Completion Date :
    Jun 1, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Eloquent function [1 year]

      The location of the eloquent function of interest (motor, sensory, speech) will be assessed pre-operatively and intra-operatively. These will be compared. Then, at 2 and 6 months post-operatively, repeat non-invasive mapping studies will be performed to compare to the subjects' prior studies. This will allow for assessment of reorganization and plasticity of function. Addtionally, novel ways of identifying eloquent brain regions will be developed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients 19 years and older.

    2. Brain tumor in or near eloquent brain regions that is appropriate for attempted resection.

    3. Appropriate body habitus and mental status/capacity to participate with non-invasive or invasive mapping.

    4. Benign or malignant intra-axial brain tumor.

    5. Primary or metastatic intra-axial brain tumor.

    Exclusion Criteria:
    1. Any patient with a contraindication to MRI (i.e. implanted devices)

    2. Inappropriate body habitus or mental status/capacity to participate with non-invasive or invasive mapping in a safe and reliable manner.

    3. Patient declines to participate.

    4. Patient that does not have the capacity to understand the study or consent for themselves.

    5. Neurologic status which precludes them from testing (poor function- not testable).

    6. Positive pregnancy test in females.

    7. Any patient with end stage renal disease or severe renal dysfunction.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Nebraska Medical Center Omaha Nebraska United States 68198

    Sponsors and Collaborators

    • University of Nebraska

    Investigators

    • Principal Investigator: Michele Aizenberg, MD, University of Nebraska

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michele Aizenberg, MD, Principal Investigator, University of Nebraska
    ClinicalTrials.gov Identifier:
    NCT01535430
    Other Study ID Numbers:
    • 671-11-FB
    First Posted:
    Feb 17, 2012
    Last Update Posted:
    Apr 28, 2022
    Last Verified:
    Apr 1, 2022
    Keywords provided by Michele Aizenberg, MD, Principal Investigator, University of Nebraska
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 28, 2022